The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Completed · Not applicable · Has a placebo group
Conditions studied: Acute Migraine
In brief
this study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relivion®)
Key facts
- Study ID
- NCT03631550
- Run by
- Neurolief Ltd.
- People needed
- 187
- Starts
- 2018-11-29
- Expected to finish
- 2020-08-04
- Last updated by the study team
- 2022-09-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects 18 years of age and older.
- Subject meets the ICHD (International Classification of Headache Disorders)-3 (2018) diagnostic criteria for Migraine with or without aura.
- Subject reports 1-6 Migraine attacks per month; other headaches no more than 6 days per month.
- Subject is willing to and capable of complying with the specified study requirements, provided written Informed Consent, can complete the electronic diaries, and can be contacted by telephone.
You may not qualify if…
- Subject having received Botox treatment in the head region in the prior 3 months.
- Subject having received supraorbital or occipital nerve blocks in the prior month.
- Past 6 months of chronic migraine, New Daily Persistent Headache, and chronic tension-type headache per ICHD-3 (2018) diagnostic criteria.
- Current medication overuse headache.
- Use of opioid medications in the prior 1 month.
- Use of barbiturates in the prior 1 month.
- Subject has >10 headache days per month
- Implanted metal/shrapnel or electrical devices in the head (not including dental implants), a cardiac pacemaker or an implanted or wearable defibrillator.
- Received parenteral infusions for migraine within the previous 2 weeks.
- Subject has known uncontrolled epilepsy.
- History of neurosurgical interventions
- Subject with implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.
- Current drug abuse or alcoholism.
- Subject is participating in any other clinical study.
- Skin lesion or inflammation at the region of the stimulating electrodes.
- Personality or somatoform disorder.
- Pregnancy or Lactation.
- Women with child bearing potential without medically acceptable method of contraception (NOTE: Females of child bearing potential must have a negative pregnancy test).
- Documented history of cerebrovascular event.
- Subject with recent brain or facial trauma (occurred less than 3 months prior to this study).
- Subject participated in a previous study with the Relivion device.
- The subject does not have the basic cognitive and motor skills needed to operate a smartphone.
- Subject with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters
- Subject with other significant pain problem that in the opinion of the investigator may confound the study assessments.
Where it is running
- Clinical Research Consortium, an AMR company — Tempe, Arizona, United States
- Hartford HealthCare Headache Center — Hartford, Connecticut, United States
- Yale School of Medicine — New Haven, Connecticut, United States
- Regeneris Medical — North Attleboro, Massachusetts, United States
- Clinical Research Consortium, an AMR company — Las Vegas, Nevada, United States
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
- Barzilai MC — Ashkelon, Israel
- Hillel Yaffe Medical Center — Hadera, Israel
- Sharei Zedek MC — Jerusalem, Israel
- Macabi healtcenter services — Kfar Saba, Israel
- Laniado MC — Netanya, Israel
- Macabi healtcenter services — Raanana, Israel
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.